Eliem Therapeutics, Inc. (ELYM)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Eliem Therapeutics, Inc. (“Eliem” or the “Company) (NASDAQ: ELYM). Investors who purchased Eliem securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Eliem and certain of its officers and/or directors have violated federal securities laws.
On or around August 9, 2021, Eliem commenced its initial public offering (“IPO”), selling 7.36 million shares of common stock priced at $12.50 per share. Then, on April 25, 2022, Eliem issued a press release “report[ing] results from its Phase 2a clinical trial investigating ETX-810 for the treatment of diabetic peripheral neuropathic pain (DPNP).” Eliem disclosed that the trial did not meet the goal of reducing pain intensity, and that the company has chosen to delay enrollment in studies of ETX-155 in depression. On this news, Eliem’s stock price fell sharply during intraday trading on April 25, 2022, damaging investors.
If you are aware of any facts relating to this investigation or purchased Eliem shares you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.